Poor nine months as Genmab waits for cost-cutting to pay off
This article was originally published in Scrip
Executive Summary
The Danish biotechnology company Genmab reported decreased revenues and increased operating losses for the nine months ended September 30th and reiterated recently revised 2009 guidance.